Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: Studies using genetically engineered mouse models

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1791, Issue 6, 2009, Pages 479-485

  Voshol, Peter J ^a   Rensen, Patrick C N ^a   van Dijk, Ko Willems ^a   Romijn, Johannes A ^a   Havekes, Louis M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Animal model; Fatty acid; Fatty acid transporter; Lipid metabolism; Lipoprotein lipase; Metabolic syndrome; Obesity; Triglyceride

Indexed keywords

ALBUMIN; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 4; APOLIPOPROTEIN; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CD36 ANTIGEN; CHYLOMICRON; FATTY ACID; LIPID; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; CYTOPLASM; DIET RESTRICTION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEEDING; GENETIC ENGINEERING; HUMAN; KINETICS; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; MEMBRANE TRANSPORT; MODEL; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; APOLIPOPROTEINS B; BIOLOGICAL TRANSPORT; DISEASE MODELS, ANIMAL; FATTY ACIDS; HUMANS; KINETICS; LIPOPROTEIN LIPASE; MICE; MICE, TRANSGENIC; OBESITY; TRIGLYCERIDES;

ANIMALIA; MUS;

EID: 67349153370     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2008.12.015     Document Type: Review

References (84)

1. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., and Pfeiffer A.F. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52 (2003) 812-817
2. Zhang C., Rexrode K.M., van Dam R.M., Li T.Y., and Hu F.B. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 117 (2008) 1658-1667
3. Chan D.T., Irish A.B., Dogra G.K., and Watts G.F. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196 (2008) 823-834
4. Rader D.J. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am. J. Med. 120 (2007) S12-18
5. Teusink B., Voshol P.J., Dahlmans V.E., Rensen P.C., Pijl H., Romijn J.A., and Havekes L.M. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 52 (2003) 614-620
6. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr. Opin. Lipidol. 8 (1997) 146-153
7. Martins I.J., and Redgrave T.G. Obesity and post-prandial lipid metabolism. Feast or famine?. J. Nutr. Biochem 15 (2004) 130-141
8. Arner P., and Langin D. The role of neutral lipases in human adipose tissue lipolysis. Curr. Opin. Lipidol. 18 (2007) 246-250
9. Duncan R.E., Ahmadian M., Jaworski K., Sarkadi-Nagy E., and Sul H.S. Regulation of lipolysis in adipocytes. Annu. Rev. Nutr. 27 (2007) 79-101
10. Zechner R., Strauss J.G., Haemmerle G., Lass A., and Zimmermann R. Lipolysis: pathway under construction. Curr. Opin. Lipidol. 16 (2005) 333-340
11. Haemmerle G., Zimmermann R., and Zechner R. Letting lipids go: hormone-sensitive lipase. Curr. Opin. Lipidol. 14 (2003) 289-297
12. Shelness G.S., and Sellers J.A. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 12 (2001) 151-157
13. Olivecrona T., Hultin M., Bergo M., and Olivecrona G. Lipoprotein lipase: regulation and role in lipoprotein metabolism. Proc. Nutr. Soc. 56 (1997) 723-729
14. Redgrave T.G. Chylomicron metabolism. Biochem. Soc. Trans. 32 (2004) 79-82
15. Havel R.J. Postprandial lipid metabolism: an overview. Proc. Nutr. Soc. 56 (1997) 659-666
16. Havel R.J. Chylomicron remnants: hepatic receptors and metabolism. Curr. Opin. Lipidol. 6 (1995) 312-316
17. Brickerton A.S.T., Roberts R., Fielding B.A., Hodson L., Blaak E.E., Wagenmakers A.J.M., Gilbert M., Karpe F., and Frayn K.N. Preferential uptake of dietary fatty acids in adipose tissue and muscle in the postprandial period. Diabetes 56 (2007) 168-176
18. Votruba S.B., Mattison R.S., Dumesic D.A., Koutsari C., and Jensen M.D. Meal fatty acid uptake in visceral fat in women. Diabetes 56 (2007) 2589-2597
19. I.G. Goldberg, R.H. Eckel, N.A. Abumrad, Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways, J. Lipid Res. (in press).
20. Coleman T., Seip R.L., Gimble J.M., Lee D., Maeda N., and Semenkovich C.F. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270 (1995) 12518-12525
21. Zechner R., Strauss J., Frank S., Wagner E., Hofmann W., Kratky D., Hiden M., and Levak-Frank S. The role of lipoprotein lipase in adipose tissue development and metabolism. Int. J. Obes. Relat. Metab. Disord. 24 Suppl 4 (2000) S53-56
22. Ferreira L.D., Pulawa L.K., Jensen D.R., and Eckel R.H. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 50 (2001) 1064-1068
23. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Lutz E.P., Kako Y., Velez-Carrasco W., Goldberg I.J., Breslow J.L., and Shulman G.I. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7522-7527
24. Voshol P.J., Jong M.C., Dahlmans V.E., Kratky D., Levak-Frank S., Zechner R., Romijn J.A., and Havekes L.M. In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes 50 (2001) 2585-2590
25. Jensen D.R., Schlaepfer I.R., Morin C.L., Pennington D.S., Marcell T., Ammon S.M., Gutierrez-Hartmann A., and Eckel R.H. Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. Am. J. Physiol. 273 (1997) R683-689
26. Weinstock P.H., Levak-Frank S., Hudgins L.C., Radner H., Friedman J.M., Zechner R., and Breslow J.L. Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10261-10266
27. Hensley L.L., Ranganathan G., Wagner E.M., Wells B.D., Daniel J.C., Vu D., Semenkovich C.F., Zechner R., and Kern P.A. Transgenic mice expressing lipoprotein lipase in adipose tissue. Absence of the proximal 3′-untranslated region causes translational upregulation. J. Biol. Chem. 278 (2003) 32702-32709
28. Fojo S.S., and Brewer H.B. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J. Intern. Med. 231 (1992) 669-677
29. Rensen P.C., and van Berkel T.J. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271 (1996) 14791-14799
30. Schaap F.G., Rensen P.C., Voshol P.J., Vrins C., Van Der Vliet H.N., Chamuleau R.A., Havekes L.M., Groen A.K., and Van Dijk K.W. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279 (2004) 27941-27947
31. Berbee J.F., van der Hoogt C.C., Sundararaman D., Havekes L.M., and Rensen P.C. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46 (2005) 297-306
32. Ito Y., Azrolan N., O'Connell A., Walsh A., and Breslow J.L. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249 (1990) 790-793
33. Koster A., Chao Y.B., Mosior M., Ford A., Gonzalez-DeWhitt P.A., Hale J.E., Li D., Qiu Y., Fraser C.C., Yang D.D., Heuer J.G., Jaskunas S.R., and Eacho P. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146 (2005) 4943-4950
34. Yagyu H., Lutz E.P., Kako Y., Marks S., Hu Y., Choi S.Y., Bensadoun A., and Goldberg I.J. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J. Biol. Chem. 277 (2002) 10037-10043
35. van Dijk K.W., Rensen P.C., Voshol P.J., and Havekes L.M. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr. Opin. Lipidol. 15 (2004) 239-246
36. Duivenvoorden I., Teusink B., Rensen P.C., Romijn J.A., Havekes L.M., and Voshol P.J. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 54 (2005) 664-671
37. Westerterp M., Berbee J.F., Delsing D.J., Jong M.C., Gijbels M.J., Dahlmans V.E., Offerman E.H., Romijn J.A., Havekes L.M., and Rensen P.C. Apolipoprotein C-I binds free fatty acids and reduces their intracellular esterification. J. Lipid Res. 48 (2007) 1353-1361
38. Jong M.C., van Dijk K.W., Dahlmans V.E., Van der Boom H., Kobayashi K., Oka K., Siest G., Chan L., Hofker M.H., and Havekes L.M. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem. J. 338 Pt 2 (1999) 281-287
39. Takahashi S., Suzuki J., Kohno M., Oida K., Tamai T., Miyabo S., Yamamoto T., and Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J. Biol. Chem. 270 (1995) 15747-15754
40. Jong M.C., Voshol P.J., Muurling M., Dahlmans V.E., Romijn J.A., Pijl H., and Havekes L.M. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 50 (2001) 2779-2785
41. Jong M.C., Rensen P.C., Dahlmans V.E., van der Boom H., van Berkel T.J., and Havekes L.M. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42 (2001) 1578-1585
42. Gautier T., Masson D., Jong M.C., Duverneuil L., Le Guern N., Deckert V., Pais de Barros J.P., Dumont L., Bataille A., Zak Z., Jiang X.C., Tall A.R., Havekes L.M., and Lagrost L. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice. J. Biol. Chem. 277 (2002) 31354-31363
43. Wroblewski M.S., Wilson-Grady J.T., Martinez M.B., Kasthuri R.S., McMillan K.R., Flood-Urdangarin C., and Nelsestuen G.L. A functional polymorphism of apolipoprotein C1 detected by mass spectrometry. FEBS J. 273 (2006) 4707-4715
44. Kasthuri R.S., McMillan K.R., Flood-Urdangarin C., Harvey S.B., Wilson-Grady J.T., and Nelsestuen G.L. Correlation of a T45S variant of apolipoprotein C1 with elevated BMI in persons of American Indian and Mexican ancestries. Int. J. Obes. 31 (2007) 1334-1336 (Lond)
45. Huang Y., Liu X.Q., Rall Jr. S.C., Taylor J.M., von Eckardstein A., Assmann G., and Mahley R.W. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273 (1998) 26388-26393
46. Hofmann S.M., Perez-Tilve D., Greer T.M., Coburn B.A., Grant E., Basford J.E., Tschop M.H., and Hui D.Y. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 57 (2008) 5-12
47. Chiba T., Nakazawa T., Yui K., Kaneko E., and Shimokado K. VLDL induces adipocyte differentiation in ApoE-dependent manner. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1423-1429
48. Gao J., Katagiri H., Ishigaki Y., Yamada T., Ogihara T., Imai J., Uno K., Hasegawa Y., Kanzaki M., Yamamoto T.T., Ishibashi S., and Oka Y. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 56 (2007) 24-33
49. Obunike J.C., Lutz E.P., Li Z., Paka L., Katopodis T., Strickland D.K., Kozarsky K.F., Pillarisetti S., and Goldberg I.J. Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J. Biol. Chem. 276 (2001) 8934-8941
50. Goudriaan J.R., Espirito Santo S.M., Voshol P.J., Teusink B., Willems Van Dijk K., Van Vlijmen B.J., Romijn J.A., Havekes L.M., and Rensen P.C. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J. Lipid Res. 45 (2004) 1475-1481
51. Goudriaan J.R., Tacken P.J., Dahlmans V.E., Gijbels M.J., van Dijk K.W., Havekes L.M., and Jong M.C. Protection from obesity in mice lacking the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1488-1493
52. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., Krauss R.M., and Rubin E.M. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
53. Mandard S., Zandbergen F., van Straten E., Wahli W., Kuipers F., Muller M., and Kersten S. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281 (2006) 934-944
54. Lichtenstein L., Berbee J.F., van Dijk S.J., van Dijk K.W., Bensadoun A., Kema I.P., Voshol P.J., Muller M., Rensen P.C., and Kersten S. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2420-2427
55. Sukonina V., Lookene A., Olivecrona T., and Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 17450-17455
56. Gimeno R.E. Fatty acid transport proteins. Curr. Opin. Lipidol. 18 (2007) 271-276
57. Stahl A. A current review of fatty acid transport proteins (SLC27). Pflugers Arch. 447 (2004) 722-727
58. Chiu H.C., Kovacs A., Blanton R.M., Han X., Courtois M., Weinheimer C.J., Yamada K.A., Brunet S., Xu H., Nerbonne J.M., Welch M.J., Fettig N.M., Sharp T.L., Sambandam N., Olson K.M., Ory D.S., and Schaffer J.E. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96 (2005) 225-233
59. Chiu H.C., Kovacs A., Ford D.A., Hsu F.F., Garcia R., Herrero P., Saffitz J.E., and Schaffer J.E. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107 (2001) 813-822
60. Kim J.K., Gimeno R.E., Higashimori T., Kim H.J., Choi H., Punreddy S., Mozell R.L., Tan G., Stricker-Krongrad A., Hirsch D.J., Fillmore J.J., Liu Z.X., Dong J., Cline G., Stahl A., Lodish H.F., and Shulman G.I. Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J. Clin. Invest. 113 (2004) 756-763
61. Wu Q., Ortegon A.M., Tsang B., Doege H., Feingold K.R., and Stahl A. FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity. Mol. Cell. Biol. 26 (2006) 3455-3467
62. Blackburn C., Guan B., Brown J., Cullis C., Condon S.M., Jenkins T.J., Peluso S., Ye Y., Gimeno R.E., Punreddy S., Sun Y., Wu H., Hubbard B., Kaushik V., Tummino P., Sanchetti P., Yu Sun D., Daniels T., Tozzo E., Balani S.K., and Raman P. Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. Bioorg. Med. Chem. Lett. 16 (2006) 3504-3509
63. Doege H., Baillie R.A., Ortegon A.M., Tsang B., Wu Q., Punreddy S., Hirsch D., Watson N., Gimeno R.E., and Stahl A. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130 (2006) 1245-1258
64. Hubbard B., Doege H., Punreddy S., Wu H., Huang X., Kaushik V.K., Mozell R.L., Byrnes J.J., Stricker-Krongrad A., Chou C.J., Tartaglia L.A., Lodish H.F., Stahl A., and Gimeno R.E. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130 (2006) 1259-1269
65. Febbraio M., Guy E., Coburn C., Knapp Jr. F.F., Beets A.L., Abumrad N.A., and Silverstein R.L. The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36. Mol. Cell. Biochem. 239 (2002) 193-197
66. Febbraio M., Abumrad N.A., Hajjar D.P., Sharma K., Cheng W., Pearce S.F., and Silverstein R.L. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274 (1999) 19055-19062
67. Ibrahimi A., Bonen A., Blinn W.D., Hajri T., Li X., Zhong K., Cameron R., and Abumrad N.A. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J. Biol. Chem. 274 (1999) 26761-26766
68. Goudriaan J.R., Dahlmans V.E., Febbraio M., Teusink B., Romijn J.A., Havekes L.M., and Voshol P.J. Intestinal lipid absorption is not affected in CD36 deficient mice. Mol. Cell. Biochem. 239 (2002) 199-202
69. Coburn C.T., Knapp Jr. F.F., Febbraio M., Beets A.L., Silverstein R.L., and Abumrad N.A. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem. 275 (2000) 32523-32529
70. Goudriaan J.R., den Boer M.A., Rensen P.C., Febbraio M., Kuipers F., Romijn J.A., Havekes L.M., and Voshol P.J. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J. Lipid Res. 46 (2005) 2175-2181
71. Wolfrum C., Borrmann C.M., Borchers T., and Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2323-2328
72. Martin G.G., Atshaves B.P., McIntosh A.L., Mackie J.T., Kier A.B., and Schroeder F. Liver fatty acid binding protein gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol.: Gasterointest. Liver Physiol. 290 (2006) G36-48
73. Newberry E.P., Xie Y., Kennedy S.M., Luo J., and Davidson N.O. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 44 (2006) 1191-1205
74. Shearer J., Fueger P.T., Bracy D.P., Wasserman D.H., and Rottman J.N. Partial gene deletion of heart-type fatty acid-binding protein limits the severity of dietary-induced insulin resistance. Diabetes 54 (2005) 3133-3139
75. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., and Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274 (1996) 1377-1379
76. Uysal K.T., Scheja L., Wiesbrock S.M., Bonner-Weir S., and Hotamisligil G.S. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141 (2000) 3388-3396
77. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., Cao Q., Atsumi G., Malone H., Krishnan B., Minokoshi Y., Kahn B.B., Parker R.A., and Hotamisligil G.S. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell. Metab. 1 (2005) 107-119
78. Boord J.B., Maeda K., Makowski L., Babaev V.R., Fazio S., Linton M.F., and Hotamisligil G.S. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 110 (2004) 1492-1498
79. Makowski L., and Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr. Opin. Lipidol. 16 (2005) 543-548
80. Takahashi S., and Satozawa N. The 20-kD human growth hormone reduces body fat by increasing lipolysis and decreasing lipoprotein lipase activity. Horm. Res. 58 (2002) 157-164
81. Brun L.D., Gagne C., Julien P., Tremblay A., Moorjani S., Bouchard C., and Lupien P.J. Familial lipoprotein lipase-activity deficiency: study of total body fatness and subcutaneous fat tissue distribution. Metabolism 38 (1989) 1005-1009
82. Ullrich N.F., Purnell J.Q., and Brunzell J.D. J. Investig. Med. 49 (2001) 273-275
83. de Graaf J., Hoffer M.J., Stuyt P.M., Frants R.R., and Stalenhoef A.F. Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCII gene and the first APOCIV gene mutation: APOCII-CIV(Nijmegen). Biochem. Biophys. Res. Commun. 273 (2000) 1084-1087
84. van der Ham R.L., Alizadeh Dehnavi R., Berbée J.F., Putter H., de Roos A., Romijn J.A., Rensen P.C.N., and Tamsma J.T. Plasma Apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome. Diabetes Care 32 (2009) 184-186